{"filings":[{"id":2106371,"accession_number":"0001437749-26-026282","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2026-08-06T20:19:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q2 net income $8.2M, raises 2026 guidance on NERLYNX demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $53.6M (+9% YoY); GAAP net income $8.2M ($0.16/sh) vs $5.9M ($0.12/sh) in Q2 2025.","Non-GAAP adjusted net income $10.1M ($0.20/sh basic) vs $7.5M ($0.15/sh) prior year.","Raises FY 2026 net product revenue guidance to $205-209M (prior $202-206M); net income to $17-20M (prior $16-19M).","Debt fully repaid in May 2026; cash & securities $93.9M at June 30, 2026.","R&D expenses rose $9.4M YTD on alisertib trial activity; milestones include ALISCA-Lung2 initiation in Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083797,"accession_number":"0001437749-26-020793","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2026-06-16T20:06:06+00:00","items":["5.07"],"status":"ready","headline":"Puma shareholders reject CEO Auerbach's warrant extension to Oct 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected; KPMG ratified as auditor for fiscal 2026.","Advisory say-on-pay approved: 29.3M for, 7.9M against, 0.7M abstain.","Warrant amendment defeated: 18.2M for, 19.6M against, 0.09M abstain.","CEO Auerbach's warrant expires Oct 4, 2026; exercisable at $16 for 2.1M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92639,"accession_number":"0001437749-26-015621","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q1 net loss $3.8M; raises 2026 revenue and net income guidance on NERLYNX demand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $42.0M vs $43.1M YoY; GAAP net loss $3.8M ($0.07/share) vs net income $3.0M.","Non-GAAP adjusted net loss $1.9M ($0.04/share) vs adjusted net income $5.0M ($0.10) YoY.","FY 2026 guidance raised: net product revenue $202-206M (prior $194-198M); net income $16-19M (prior $10-13M).","Debt fully repaid on May 4, 2026; cash & securities $101.5M at March 31, 2026, up from $97.5M.","Second-quarter Q2 2026 net product revenue guidance $50-52M, net income $2-4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":44814000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103612,"accession_number":"0001437749-26-005869","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q4 2025 revenue $75.5M, GAAP net income $13.4M; guides FY2026 net income $10-13M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 product revenue $59.9M (+10% YoY); total revenue $75.5M vs $59.1M YoY including $15.6M royalty.","GAAP net income Q4 2025 $13.4M ($0.27 basic) vs $19.3M ($0.39) YoY; non-GAAP adjusted net income $15.1M ($0.30).","Full year 2025 total revenue $228.4M; GAAP net income $31.1M ($0.62) vs $30.3M ($0.62) YoY.","Cash, equivalents & marketable securities $97.5M; total debt reduced to $22.5M from $67.0M at end of 2024.","FY2026 guidance: net product revenue $194-198M; total revenue $214-221M; net income $10-13M, excluding valuation allowance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":228371000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119878,"accession_number":"0001437749-25-033604","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).","Q3 product revenue $51.9M (vs $56.1M); total revenue $54.5M (vs $80.5M) driven by lower royalty from China licensee.","Updated FY2025 guidance: product revenue $198-200M, total revenue $220-223M, net income $27-29M (all raised from prior).","Cash & securities $94.4M at Sep 30, 2025; operating cash flow $9.7M in Q3.","Interim data from ALISCA-Breast1 and ALISCA-Lung1 alisertib trials expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":152918000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136443,"accession_number":"0001437749-25-025463","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.","Net product revenue $49.2M (+11% YoY); total revenue $52.4M (+11% YoY).","Q3 2025 guidance: net product revenue $46–48M, total revenue $48–51M, net income $2–4M.","Full-year 2025 revenue outlook reaffirmed at $212–222M; gross-to-net adjustment raised to 21.5–22.0%.","Cash & equivalents $96M; key milestones: alisertib interim data in Q4 2025 for two Phase II trials."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":98443000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153603,"accession_number":"0001437749-25-021153","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Puma Biotechnology amends bylaws to align with Delaware law updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Fifth Amended and Restated Bylaws on June 19, 2025.","Changes primarily reflect updates to Delaware General Corporation Law.","Includes conforming, ministerial, and other related revisions.","No substantive operational or financial changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153602,"accession_number":"0001437749-25-020321","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Puma Biotechnology shareholders elect directors, ratify KPMG, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight directors elected; Troy E. Wilson received 24.3M for, 10.7M withheld, the largest withhold among nominees.","Ratification of KPMG as independent auditor for FY2025 passed with 40.7M for, 0.7M against.","Advisory vote on named executive officer compensation approved with 32.6M for, 1.7M against, 0.7M abstain.","6.5M broker non-votes were recorded on director election and say-on-pay, not on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153601,"accession_number":"0001437749-25-015648","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Puma Biotechnology terminates CCO Jeff J. Ludwig; no replacement named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Jeff J. Ludwig as Chief Commercial Officer and employee on May 8, 2025.","Mr. Ludwig may receive severance per his employment offer letter contingent on signing a release within 60 days.","Company will not appoint a new CCO; responsibilities absorbed by existing sales and marketing personnel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153600,"accession_number":"0001437749-25-015514","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma swings to Q1 profit; NERLYNX revenue up 7% to $43.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $3.0M ($0.06 EPS) vs net loss $4.8M ($0.10 loss) in Q1 2024.","Non-GAAP adjusted net income $5.0M ($0.10 EPS) vs adjusted loss $2.4M.","Product revenue $43.1M (+7% YoY), royalty revenue $2.9M.","Q2 2025 guidance: net product revenue $48-50M, net income $4-6M.","Cash & securities $93.2M at Mar 31, down from $101.0M at Dec 31."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":46007000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172311,"accession_number":"0001437749-25-005477","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).","GAAP net income $30.3M ($0.62/share) for FY2024 vs. $21.6M ($0.46) in FY2023.","Non-GAAP adjusted net income $38.5M ($0.79/share) for FY2024 vs. $31.8M ($0.68) in FY2023.","Cash and securities $101M at Dec 31, 2024; operating cash flow $38.9M for FY2024.","FY2025 guidance: net product revenue $192-198M; net income $23-28M (excludes valuation allowance)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":230468000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189305,"accession_number":"0001437749-24-033929","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.","GAAP EPS $0.41 diluted; adjusted non-GAAP EPS $0.45 diluted.","FY 2024 net product revenue guidance raised to $187-190M (from $183-190M); net income raised to $15-17M.","Cash & securities $97M at Sept 30; operating cash flow $11M in Q3.","Phase II alisertib trials in SCLC and breast cancer on track; interim data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":171391000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205799,"accession_number":"0001437749-24-029206","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma reports judge invalidated Tagrisso patents; Wyeth appeals Sept 12","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury awarded $107.5M for past infringement of '314 and '162 patents through Dec 2023.","Judge granted AstraZeneca's motion, ruling patents invalid for lack of enablement/written description.","Wyeth filed notice of appeal on Sept 12, 2024, challenging the invalidity ruling and other adverse orders.","Puma was dismissed as plaintiff but retains contractual rights to recover damages under Pfizer agreement.","Puma respectfully disagrees with the invalidity ruling; post-trial motions for supplemental damages and ongoing royalties pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205798,"accession_number":"0001437749-24-026953","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Court invalidates Puma's patents in Tagrisso suit, overturns $107.5M jury award","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Tagrisso infringed Puma's patents, awarded $107.5M in damages.","Judge overturned verdict, ruling patents invalid under §112 for lack of enablement/written description.","Final judgment entered; Puma can appeal by Sept 13, 2024.","Puma dismissed as plaintiff but retains contractual rights to damages via Wyeth; ruling affects potential recovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205797,"accession_number":"0001437749-24-025027","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma Biotechnology wins patent suit vs AstraZeneca; $107.5M jury award upheld in bench trial","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found Tagrisso infringes Wyeth's patents; damages of $107.5M for past infringement through Dec 31, 2023.","Bench trial on equitable claims ruled in Wyeth's favor; all AstraZeneca defenses rejected.","Puma maintains contractual rights to recover monetary damages under license with Pfizer.","Post-trial motions pending; AstraZeneca seeks new trial, Wyeth seeks supplemental damages and ongoing royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205796,"accession_number":"0001437749-24-024297","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Q2 NERLYNX revenue $44.4M (-14% YoY); GAAP net loss $4.5M vs profit $2.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 product revenue $44.4M (down from $51.6M in Q2 2023); total revenue $47.1M incl $2.7M royalties.","GAAP net loss $4.5M ($0.09 loss per share) vs net income $2.1M ($0.05 EPS) in Q2 2023.","Non-GAAP adjusted net loss $2.5M ($0.05 loss per share) vs adjusted net income $4.6M ($0.10 EPS).","Cash & equivalents $96.8M at June 30, 2024; net cash from ops $1.0M in Q2.","FY2024 guidance: net product revenue $183-190M, net income $12-15M; Q3 net product revenue $50-53M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":90849000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222774,"accession_number":"0001437749-24-021086","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Puma Biotechnology shareholders approve 3M share increase for equity plan, elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase shares under 2011 plan by 3M to 17,529,412; ISO grants extended to March 2034.","All eight director nominees elected: Auerbach, Cesano, Dorval, Miller, Moyes, Senderowicz, Stuglik, Wilson.","Ratified KPMG as independent auditor for fiscal 2024 with 40.2M votes for.","Advisory say-on-pay approved with 30.7M for; board adopts annual frequency for future votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222773,"accession_number":"0001437749-24-017504","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Jury awards Puma/Wyeth $107.5M in Tagrisso patent infringement case vs AstraZeneca","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Jury found '314 and '162 patents infringed and not invalid; damages $107.5M for past acts.","Puma was dismissed as plaintiff but retains contractual right to recover damages under Pfizer license.","Bench trial on equitable defenses (unclean hands, patent misuse) set for June 17-18, 20, 2024.","Further proceedings will determine ongoing royalty rate through patent term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222772,"accession_number":"0001437749-24-014382","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.","GAAP net loss $0.10/shr; non-GAAP adjusted net loss $0.05/shr vs adjusted net income $0.09/shr in Q1 2023.","Cash, cash equivalents and marketable securities $107.2M at March 31, 2024; operating cash flow $11.3M.","Q2 2024 guidance: net product revenue $43-45M, net loss $(6)-(9)M; FY2024: product revenue $183-190M, net income $12-15M.","Initiated alisertib Phase II trial in small cell lung cancer (ALISCA-Lung1); key milestones through Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":43766000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242259,"accession_number":"0001437749-24-008508","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma partially dismissed as plaintiff in Tagrisso patent suit; trial set May 13","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Court denied AstraZeneca's motions for patent invalidity and summary judgment of non-infringement.","AstraZeneca's motion to dismiss Puma as plaintiff granted on standing grounds; Puma remains counterclaim-defendant.","Puma retains contractual rights under Pfizer license to seek monetary damages in the case.","Jury trial scheduled for May 13, 2024 in Delaware federal court.","Suit alleges Tagrisso infringes patents licensed exclusively to Puma; Wyeth continues as co-plaintiff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242258,"accession_number":"0001437749-24-006099","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology reports Q4 GAAP net income of $12.3M; guides Q1 2024 net loss of $10-12M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue net Q4 $53.2M (flat YoY); full year $203.1M, up from $200.0M.","GAAP net income Q4 $12.3M ($0.26/diluted) vs net loss $5.6M in Q4 2022.","Non-GAAP adjusted net income Q4 $14.8M ($0.31/share) vs adjusted net loss $3.0M.","Cash and marketable securities $96.0M at Dec 31, 2023, up from $81.1M a year ago.","Guidance: Q1 2024 net product revenue $38-40M, net loss $10-12M; FY2024 net income $12-15M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":235637000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242257,"accession_number":"0001437749-24-001581","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Puma Biotechnology presents at B. Riley Oncology Conference; no material new information disclosed.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation at B. Riley Securities 4th Annual Oncology Conference on January 18, 2024.","Chairman, President and CEO Alan H. Auerbach to present.","Exhibit 99.1 presentation not included as extractable text; specifics unavailable.","No financial or operational updates disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259658,"accession_number":"0001437749-23-030014","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q3 2023 net income $5.8M, reverses prior-year loss; revenue $56.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue net $51.6M (down 5% YoY from $54.3M); total revenue $56.1M.","GAAP net income $5.8M ($0.12/diluted) vs net loss $0.4M in Q3 2022.","Non-GAAP adjusted net income $8.3M ($0.17/diluted) vs $2.5M prior year.","Cash and securities $85.0M; net cash from operations $10.7M in Q3.","Q4 product revenue guidance $56-59M; FDA accepted IND for alisertib, granted orphan drug designation for SCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":163459000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276926,"accession_number":"0001437749-23-026766","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Puma announces acceptance of alisertib + pembrolizumab poster at AACR-NCI-EORTC conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Investigator-sponsored Phase I/II trial of alisertib plus pembrolizumab accepted for poster presentation.","Trial targets Rb-deficient head and neck squamous cell carcinoma (HNSCC).","Poster presentation at late-breaking session C on Oct 14, 2023, 12:30-4:00 pm ET, as LB_C12.","Conference: 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.","No clinical data results announced; this is a trial update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276925,"accession_number":"0001437749-23-024168","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-08-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Puma Biotechnology amends bylaws to align with universal proxy rules and enhance stockholder disclosure requirements","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Fourth Amended and Restated Bylaws on August 17, 2023, effective immediately.","Amendments address universal proxy rules under Rule 14a-19, requiring compliance for non-board solicitations.","Non-board proxy solicitations must use a proxy card color other than white, reserved for Board use.","Enhanced advance notice disclosure for stockholders proposing business or nominating directors, including ownership and litigation info.","Technical updates to align with Delaware General Corporation Law and Exchange Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276924,"accession_number":"0001437749-23-021937","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q2 net income $2.1M, down from $9.4M YoY; revenue flat at $51.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $2.1M ($0.05/diluted share) vs $9.4M ($0.21) Q2 2022; non-GAAP adj net income $4.6M ($0.10).","Product revenue from NERLYNX $51.6M, slightly up from $51.3M YoY; royalty revenue fell to $3.0M from $8.2M.","Net cash from operations positive $3.3M vs -$13.9M Q2 2022; cash & securities $74.4M at June 30.","FY 2023 guidance: product revenue $205-210M, net income $20-24M; Q3 product revenue guided $51-53M.","Pipeline milestones: Phase II alisertib in small cell lung cancer H2 2023; FDA meeting Q4 for HR+ HER2- breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":107343000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294766,"accession_number":"0001437749-23-017581","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Puma Biotechnology announces results of 2023 annual meeting of stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; highest 'for' vote was Cesano at 30,203,447, lowest was Wilson at 26,825,653.","KPMG LLP ratified as independent auditor for FY2023 with 39,051,453 votes for, 113,960 against.","Advisory say-on-pay proposal approved: 28,584,098 for, 2,112,789 against, 113,566 abstain.","Broker non-votes of 8,447,026 recorded on director election and say-on-pay proposals.","No other proposals or material business conducted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294765,"accession_number":"0001437749-23-012576","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q1 net income $1.4M vs loss; NERLYNX revenue $46.8M (+15% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $1.4M ($0.03/diluted share) vs net loss of $3.4M in Q1 2022.","Non-GAAP adjusted net income $4.2M ($0.09/share) vs adjusted net loss of $0.3M.","Q1 product revenue (NERLYNX) $46.8M, up from $40.7M YoY; royalty revenue $6.0M.","Cash and marketable securities $71.2M at March 31, 2023 vs $81.1M at Dec 31, 2022.","Guidance: FY 2023 net product revenue $205-210M; net income $20-24M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":52775000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315354,"accession_number":"0001437749-23-005220","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q4 net loss $5.6M; FY net income $0; guides FY2023 product rev $205-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $53.7M (+5% YoY); full year $200.0M (+6% YoY).","Q4 GAAP net loss $5.6M ($0.12/sh) vs net income $4.2M in Q4 2021; includes $12.4M legal accrual.","Full year 2022 GAAP net income $0.0M ($0.00/sh) vs net loss $29.1M in 2021.","Non-GAAP adjusted net income FY2022 $11.8M ($0.26/sh) vs $3.5M ($0.09/sh) in 2021.","FY2023 guidance: product revenue $205-210M, royalty rev $25-30M, net income $20-24M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315353,"accession_number":"0001437749-23-000699","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Puma Biotechnology files 8-K for investor presentations; no material new info disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Chairman, President & CEO Alan Auerbach to present at investor conferences starting Jan 9, 2023.","Presentation materials furnished as Exhibit 99.1; no specific financial or operational updates in filing text.","No earnings, guidance, or corporate events announced in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333703,"accession_number":"0001437749-22-029261","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Puma settles Neratinib patent litigation with Sandoz; generic entry allowed Dec 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement and License Agreement with Sandoz fully resolves pending Hatch-Waxman litigation in New Jersey.","Sandoz receives a non-exclusive, royalty-free sublicense to key patents, including U.S. Patent No. 7,399,865 B2.","Sandoz may begin selling generic Neratinib on or about December 8, 2030, subject to adjustment.","Company and Wyeth also grant Sandoz a waiver of all regulatory exclusivities.","Settlement eliminates burden, expense, and uncertainties of further litigation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333702,"accession_number":"0001437749-22-028937","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Puma Biotechnology sells $2.5M of common stock to CEO Alan Auerbach in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 568,181 shares of common stock to CEO Alan Auerbach at $4.40/share, gross proceeds ~$2.5M.","Purchase price equaled December 9, 2022 closing price; private placement closed December 12, 2022.","Shares issued under Section 4(a)(2) exemption, not registered under Securities Act.","Proceeds for general corporate purposes; no specific use disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333701,"accession_number":"0001437749-22-028774","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Puma Biotechnology presents materials at San Antonio Breast Cancer Symposium; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company representatives presented a poster at the San Antonio Breast Cancer Symposium on December 9, 2022.","No financial or clinical results were disclosed in the filing.","The presentation was furnished under Regulation FD and is not filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333700,"accession_number":"0001437749-22-028687","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Puma presents Phase II TBCRC-022 data: neratinib+T-DM1 achieves CNS ORR 28-33% in HER2+ BCBM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CNS objective response rate by RANO-BM: 33.3% (cohort 4A), 29.4% (4B), 28.6% (4C).","Response + stable disease ≥6 months: 50% (4A), 35.3% (4B), 33.3% (4C).","Intracranial activity observed including prior T-DM1 exposure, suggesting reversal of resistance.","Most common adverse event: diarrhea (grade 2 32%, grade 3 23%); prophylaxis required.","Data from prospective, multicenter Phase II study; presented at San Antonio Breast Cancer Symposium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333699,"accession_number":"0001437749-22-026924","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Puma Biotechnology settles defamation lawsuit for $16M; payments due in 2023 and 2024","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Dr. Fredric Eshelman for $16M resolves defamation lawsuit; no admission of liability.","First payment of $8M due by Jan 31, 2023; second payment of $8M due by Nov 1, 2024.","Original jury award of $22.4M vacated on appeal; settlement avoids new trial on damages.","Lawsuit dismissed with prejudice; each party bears its own costs and fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333698,"accession_number":"0001437749-22-025761","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q3 net loss narrows to $0.4M; raises FY 2022 NERLYNX revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 product revenue $54.3M, up 25% YoY from $43.4M; net loss $0.4M ($0.01/share) vs $44.7M loss in Q3 2021.","Non-GAAP adjusted net income $2.5M ($0.05/share) vs adjusted loss of $40.4M a year ago.","Raises FY 2022 product revenue guidance to $194-$196M from prior $180-$190M; net income guidance $7-$9M.","In-licensed alisertib (aurora kinase A inhibitor) from Takeda for $7M upfront; plans initial trials in HR+ breast cancer and small cell lung cancer.","Cash and marketable securities $78.0M at Sep 30, 2022; operating cash flow $17.3M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":162356000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351160,"accession_number":"0001437749-22-022922","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-09-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Puma Biotechnology licenses alisertib from Takeda; $7M upfront, up to $287.3M in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered exclusive global license for alisertib from Takeda; upfront payment of $7 million.","Potential regulatory and commercial milestones up to $287.3 million, plus tiered royalties.","Puma responsible for development, manufacturing, and commercialization globally.","Must use commercially reasonable efforts in US, UK, France, Germany, Italy, Spain, and Japan.","Puma can terminate on 120 days' notice; Takeda may terminate if Puma halts activities for >12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351159,"accession_number":"0001437749-22-019800","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Puma Biotechnology retracts defamatory statements about Dr. Frederic Eshelman after court ruling","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Retracts 2016 investor-presentation statements implying Dr. Eshelman was fired from PPD and involved in clinical fraud.","Fourth Circuit affirmed liability verdict on June 23, 2021, but vacated excessive damages award.","Company states no portion of presentation should be interpreted to suggest Eshelman fired or implicated in fraud."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351158,"accession_number":"0001437749-22-018894","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech swings to Q2 profit of $0.21/sh; NERLYNX revenue up 5%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $9.4M ($0.21 per share) vs net loss of $5.1M ($0.13 loss) in Q2 2021.","Total revenue $59.5M ($51.3M product, $8.2M royalties) vs $53.4M in Q2 2021.","Operating expenses fell sharply: SG&A $20.6M (down 48%), R&D $11.9M (down 36%).","Cash and securities $60.8M at June 30, down from $82.1M at Dec 31, 2021.","Management guides for FDA meetings on registration pathways for neratinib in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":105254000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351157,"accession_number":"0001437749-22-018452","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Puma Biotechnology appoints Alessandra Cesano to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cesano appointed effective July 29, 2022, also to R&D Committee.","She has served as CMO of ESSA Pharmaceuticals since 2019, previously CMO at NanoString.","Received option to purchase 100,000 shares at $2.93/share, vesting over 3 years.","Term expires at 2023 Annual Meeting; standard director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368437,"accession_number":"0001437749-22-015291","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Puma Biotechnology shareholders elect directors, ratify KPMG, approve say-on-pay at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected: Auerbach (29.9M for, 0.9M withheld), Wilson (20.4M for, 10.4M withheld).","KPMG ratified as independent auditor for FY2022 with 37.1M votes for, 0.5M against, 0.1M abstain.","Advisory vote on executive compensation approved: 27.1M for, 3.6M against, 0.1M abstain, with 6.95M broker non-votes.","Meeting held June 14, 2022; all proposals passed with broker non-votes on director and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368436,"accession_number":"0001437749-22-011132","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q1 net loss $3.4M, product revenue down 11% to $40.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $3.4M ($0.08 per share) vs net income of $16.5M ($0.41) in Q1 2021.","Total revenue $45.7M vs $98.2M; product revenue $40.7M (down 11% YoY); royalty revenue $5.0M.","Non-GAAP adjusted net loss $0.3M ($0.01 per share) vs adjusted net income $22.4M ($0.56) a year ago.","Cash and marketable securities $73.9M at March 31, 2022, down from $82.1M at Dec 31, 2021.","Upcoming milestones for neratinib trials: SUMMIT Phase II data in HER2-mutated breast cancer and biliary tract cancer H1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":45736000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387743,"accession_number":"0001437749-22-006127","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Puma Biotechnology raises $10M via private placement with CEO and Athyrium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,584,228 shares at $2.79 each to CEO Alan Auerbach and an Athyrium fund for $10M gross proceeds.","Each purchaser committed ~$5M; placement closed March 10, 2022, at closing price.","Proceeds will be used for general corporate purposes; company to file resale registration statement within 135 days.","Private placement exempt from registration under Section 4(a)(2) of Securities Act.","CEO Auerbach participated alongside Athyrium, an existing noteholder affiliate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387742,"accession_number":"0001437749-22-005156","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Q4 net income $4.2M vs loss; FY loss narrows to $29.1M from $60.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product revenue $51.0M (+2% YoY); total revenue $55.4M including $1.5M license and $2.9M royalty.","GAAP net income Q4 $4.2M ($0.10 EPS) vs loss of $15.0M ($0.38 loss) in Q4 2020.","FY 2021 net loss $29.1M ($0.72 loss) vs $60.0M loss ($1.52 loss); non-GAAP adjusted net income $3.5M.","Cash and securities $82.1M at Dec 31; operating cash flow $20.7M provided in FY 2021 vs $0.8M in FY 2020.","Key 2022 catalysts: pre-NDA meeting for neratinib HER2-mutant breast cancer, Phase II data in multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387741,"accession_number":"0001437749-22-000622","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Puma Biotechnology CEO to present at investor conferences beginning Jan 10, 2022","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Alan Auerbach will present at conferences and other forums starting January 10, 2022.","Presentation slides attached as Exhibit 99.1 contain the information to be disclosed.","No specific financial or operational details from the slides are available in this filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405684,"accession_number":"0001437749-21-028442","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2021-12-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Ann Miller to resign from Puma Biotechnology board effective Dec 31, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ann Miller notified her resignation as director on December 9, 2021, effective December 31, 2021.","Resignation is not the result of any disagreement with the company according to the filing.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405683,"accession_number":"0001437749-21-025336","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Puma Biotechnology enters into $50M at-the-market equity distribution agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $50M of common stock may be sold from time to time in ATM offerings through Jefferies LLC.","Jefferies receives 3% commission on gross proceeds; sales at prevailing market prices.","Company has no obligation to sell any shares under the agreement.","Shares offered under existing shelf registration statement (File No. 333-257687) effective July 13, 2021.","Agreement may remain effective until July 2024 unless earlier terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405682,"accession_number":"0001437749-21-025291","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotechnology Q3 net loss widens to $44.7M; product revenue falls 12%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 product revenue $43.4M, down from $49.3M YoY; COVID-19 impact and inventory reduction of ~$3.5M.","GAAP net loss $44.7M ($1.09/share) vs $31.5M ($0.79/share) in Q3 2020; non-GAAP adj. loss $40.4M.","Cash, cash equivalents, and marketable securities $87.5M at Sep 30; operating cash flow $10.5M positive.","Nine-month 2021 total revenue $197.8M included $50M upfront from Pierre Fabre for Greater China rights.","Milestones: SUMMIT trial data, FDA Type C meeting for accelerated approval in HER2-mutated breast cancer, regulatory decisions."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":197798000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424715,"accession_number":"0001193125-21-237729","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Puma Biotech Q2 2021 GAAP net loss $5.1M vs prior-year profit; NERLYNX flat at $48.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $5.1M ($0.13 loss/share) vs net income of $3.4M in Q2 2020.","Non-GAAP adjusted net income $13.1M ($0.32/share) vs $14.0M ($0.36/share) in Q2 2020.","NERLYNX net revenue $48.9M, essentially flat vs $48.8M in Q2 2020.","Cash & securities $108.9M at June 30, 2021, up from $93.4M at Dec 31, 2020.","Received label expansion for NERLYNX dose escalation; SUMMIT top-line data expected Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":151553000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":424714,"accession_number":"0001193125-21-229184","cik":1401667,"company_name":"PUMA BIOTECHNOLOGY, INC.","ticker":"PBYI","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Puma Biotechnology enters $100M note purchase agreement to refinance prior credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $100M notes to Athyrium; $25M additional available; used proceeds plus ~$9.2M to repay prior $100M facility.","Notes bear 8.0% + 3-month LIBOR; quarterly interest; principal amortization starts June 2024, maturity July 2026.","Covenants require minimum cash and minimum NERLYNX-based revenue; secured by substantially all assets including IP.","Prepayment fees: make-whole within 2 years, 2% thereafter to year 3; exit fee 2% on any prepayment.","Restrictions on additional debt, dividends, mergers, asset sales, and change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":371057031.8864569,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-29T23:59:59+00:00|424714"}